Investing

Hims & Hers : HIMS

HIMS

Stock Data

$27.41

$0.24 (0.88%)

Asset Type

Common Stock

Exchange

NYSE

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

DRUG MANUFACTURERS - SPECIALTY & GENERIC

Hims & Hers Health Inc is a telehealth company based in San Francisco, California, providing a bridge between consumers and licensed healthcare professionals across the U.S., the U.K., and other countries. The company offers a wide array of health and wellness products and services, including both prescription and non-prescription options, directly to customers through its website and app. Its offerings span general wellness, sexual health, skincare, and hair care, featuring items like medications, supplements, cosmetics, and personal care devices. Additionally, Hims & Hers Health supports ongoing care with recurring prescriptions and medical consultations.

All Hims & Hers Articles

46 Articles

David Moadel | Apr 24, 2026 at 12:01 PM EDT

JPMorgan Initiates Hims & Hers With Overweight: Could the Novo Nordisk Deal Be the Turning Point?

Hims & Hers Health (NYSE:HIMS) just picked up a high-profile endorsement. JPMorgan analyst Cory Carpenter initiated coverage with an Overweight…

Rich Duprey | Apr 21, 2026 at 12:04 PM EDT

Did Amazon Just Wreck All of Hims & Hers Upside Potential?

The GLP-1 weight-loss category exploded into a multi-billion-dollar opportunity that blends medication access with ongoing patient support. This morning, Amazon‘s…

David Moadel | Apr 20, 2026 at 10:40 AM EDT

Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal

Hims & Hers Health (NYSE:HIMS) shares are up 9% in early trading Monday, climbing from $28.82 to $31 and change…

Gerelyn Terzo | Apr 17, 2026 at 9:50 AM EDT

S&P 500 Clinches 7000, Extends Gains After Traffic Returns to Hormuz Strait

The S&P 500 (^GSPC) crossed 7,000 for the first time in history this week, closing at 7,022.95 on Wednesday before…

David Moadel | Apr 16, 2026 at 10:34 AM EDT

BofA Raises Hims & Hers Target to $25 as FDA Takes a Step Toward Wellness Peptides: Is a New Revenue Boom Coming?

Hims & Hers Health (NYSE:HIMS) just got a fresh look from Bank of America, which raised its price target on…

Rich Duprey | Mar 12, 2026 at 10:46 AM EDT

Is Hims & Hers Really the Growth Stock to Buy That It Appears?

Hims & Hers Health (NYSE:HIMS) looked like a fallen growth star earlier this year. The telehealth platform was hammered by…

David Moadel | Mar 11, 2026 at 10:10 AM EDT

Barclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang — Canaccord Cuts Progyny (PGNY) on Cautious 2026 Outlook

Two healthcare names are drawing fresh analyst attention this week as Wall Street recalibrates around a landmark GLP-1 truce and…

Joel South | Mar 10, 2026 at 10:09 AM EDT

Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles

Three health-technology names are drawing fresh analyst attention this week as strategic partnerships and business pivots reframe the risk-reward calculus…

Lee Jackson | Mar 10, 2026 at 8:06 AM EDT

Here Are Tuesday’s Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe’s, Qualcomm, Rivian, Strategy and More

Pre-Market Stock Futures: Futures are trading lower as many across Wall Street breathed a semi-sigh of relief yesterday after oil…

Gerelyn Terzo | Mar 9, 2026 at 9:58 AM EDT

Live Nasdaq Composite: Market Turmoil Persists With All Eyes On $100 Oil

This article will be updated throughout the day, so check back often for more daily updates. The markets are starting…

Rich Duprey | Mar 7, 2026 at 10:56 AM EST

Hims & Hers Surprise Rescue: Stock Explodes 40% on GLP-1 Truce

In a dramatic reversal of fortune, Hims & Hers Health (NYSE:HIMS) has been rescued by the very company that nearly…

Jordan Chussler | Feb 24, 2026 at 9:24 AM EST

Hims & Hers Stumbles at the Open as Regulatory Damage Hits 2026 Outlook Hard

Shares of Hims & Hers Health (NYSE:HIMS) are trading lower this morning after yesterday’s earnings, and the reason is straightforward:…

Trey Thoelcke | Feb 24, 2026 at 6:40 AM EST

Hims & Hers Snaps EPS Losing Streak but Shares Still in Free Fall

Hims & Hers Health (NYSE: HIMS) delivered a beat on both earnings and profitability in Q4 2025, though a soft…

Rich Duprey | Feb 20, 2026 at 11:51 AM EST

Hims & Hers $1.2 Billion Global Leap: Can Eucalyptus Cure its GLP-1 Ills?

Hims & Hers Health (NYSE:HIMS) just made a bold move to take its personalized wellness platform global. The company announced…

Joel South | Feb 16, 2026 at 11:19 AM EST

Wall Street Sees 84% Upside in Hims & Hers (HIMS) Despite This Month’s 48% Selloff

Hims & Hers Health (NYSE:HIMS) has crashed 47.96% over the past month, falling from $31.32 on January 14 to $16.30…